by Johan Lundkvist | Nov 29, 2022 | News
The US Food and Drug Administration (FDA) has approved Sinfonia’s Investigational New Drug (IND) application for phase IIb studies in chronic sciatic pain with its lead compound SB0101. The Phase IIb trial builds on positive results obtained in a previous phase IIa...
by Johan Lundkvist | Oct 20, 2022 | News
Sinfonia’s lead compound SB0101 for treatment of chronic sciatica is an injectable biologic that has demonstrated impressive pain lowering activities in clinical studies. In preparation for further clinical development, new stability data of the protein drug have been...
by Johan Lundkvist | Aug 18, 2022 | News
The current member of the Sinfonia board of directors, Olof Larsson, is entering the operational role as the company’s CSO. Olof is replacing Johan Lundkvist who is continuing as COO. Olof’s prior experience as CSO for Eli Lilly Pain and Migraine makes him a key...
by Johan Lundkvist | Jun 30, 2022 | News
Sinfonia_New board members
